circ_0001006 Promotes Immune Escape in Non-small Cell Lung Cancer by Regulating the miR-320a/PD-L1 Axis

被引:0
|
作者
Geng, Zhenying [1 ]
Zhang, Guoqing [2 ]
机构
[1] Chinese Acad Sci, Zhongguancun Hosp, Dept Oncol, Beijing 100089, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Dept Oncol, 8 East St, Beijing 100039, Peoples R China
关键词
circ_0001006; miR-320a; NSCLC; PD-L1; Progression; PD-L1; EXPRESSION; ADENOCARCINOMA; METASTASIS;
D O I
10.22034/iji.2025.102661.2792
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Circular RNAs are involved in the tumorigenesis of various tumors, including Non-small cell lung cancer (NSCLC). Objective: To investigate the expression of circ_0001006 in patients with NSCLC and its role in tumorigenesis and immune escape. Methods: A total of 115 patients with NSCLC were enrolled in the study. The expression of circ_0001006 and PD-L1 mRNA were detected using RT-qPCR. Cell proliferation activity, cell migration and invasion abilities were measured using the CCK-8 assay and Transwell chambers assay. Coculture of NSCLC cells with CD8 cytotoxic T cells was conducted to measure the levels of INF-gamma, TNF-alpha, IL-2, and lactate dehydrogenase release in culture supernatants. Bioinformatic analysis was used to predict the target relevance among circ_0001006, miR-320a, and PD-L1. Results: The circ_0001006 and PD-L1 mRNA levels were elevated in NSCLC tissues and cells. Patients with high levels of circ_0001006 had a shorter overall survival rate. Inhibiting circ_0001006 reduced the proliferation, migration, and invasion of NSCLC cells, while increasing PD-L1 partially counteracting the inhibitory effects of si-circ_0001006. The co-culture system of NSCLC and CD8+ T cell was found to reduce the viability of activated CD8+ T cell when circ_0001006 is present. Knocking down circ_0001006 in co- culture cells led to an increase in the expression of INF-gamma, TNF-alpha, and IL-2. The ability of si-circ_0001006 to enhance the activation of CD8+ T cells was diminished when PD-L1 was overexpressed. Conclusion: circ_0001006 may serve as a potential prognostic predictor and therapeutic target for NSCLC. Additionally, it offers insight into a novel regulatory mechanism of circ_0001006.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
    Dong Ha Kim
    HyeongRyul Kim
    Yun Jung Choi
    Seon Ye Kim
    Jung-Eun Lee
    Ki Jung Sung
    Young Hoon Sung
    Chan-Gi Pack
    Min-kyo Jung
    Buhm Han
    Kunhee Kim
    Woo Sung Kim
    Soo Jeong Nam
    Chang-Min Choi
    Miyong Yun
    Jae Cheol Lee
    Jin Kyung Rho
    Experimental & Molecular Medicine, 2019, 51 : 1 - 13
  • [2] Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
    Kim, Dong Ha
    Kim, HyeongRyul
    Choi, Yun Jung
    Kim, Seon Ye
    Lee, Jung-Eun
    Sung, Ki Jung
    Sung, Young Hoon
    Packd, Chan-Gi
    Jung, Min-kyo
    Han, Buhm
    Kim, Kunhee
    Kim, Woo Sung
    Nam, Soo Jeong
    Choi, Chang-Min
    Yun, Miyong
    Lee, Jae Cheol
    Rho, Jin Kyung
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2019, 51 (8): : 1 - 13
  • [3] Mechanism of the KIAA1429/KLF1/PD-L1 Axis in Regulating Immune Escape in Non-small Cell Lung Cancer
    Geng, Rui
    Ren, Mingmin
    Ma, Yuhui
    Su, Wen
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2024,
  • [4] Targeting the PD-1/PD-L1 axis in non-small cell lung cancer
    Kumar, Rajiv
    Collins, Dearbhaile
    Dolly, Saoirse
    McDonald, Fiona
    O'Brien, Mary E. R.
    Yap, Timothy A.
    CURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 111 - 124
  • [5] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Bagley, Stephen J.
    Bauml, Joshua M.
    Langer, Corey J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683
  • [6] Non-Small Cell Lung Cancer, PD-L1, and the Pathologist
    Kerr, Keith M.
    Nicolson, Marianne C.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (03) : 249 - 254
  • [7] SChLAP1 contributes to non-small cell lung cancer cell progression and immune evasion through regulating the AUF1/PD-L1 axis
    Du, Zhonghai
    Niu, Shuxian
    Wang, Juan
    Wu, Jun
    Li, Sheng
    Yi, Xiuxiu
    AUTOIMMUNITY, 2021, 54 (04) : 225 - 233
  • [8] PREDICTORS OF PD-L1 TESTING IN NON-SMALL CELL LUNG CANCER
    DiBonaventura, M.
    Meyers, A.
    Higginbottom, K.
    Morimoto, Y.
    Ilacqua, J.
    VALUE IN HEALTH, 2016, 19 (07) : A763 - A763
  • [9] Durvalumab for the treatment of PD-L1 non-small cell lung cancer
    Naito, Tomoyuki
    Shiraishi, Hideaki
    Fujiwara, Yutaka
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (02): : 95 - 105
  • [10] Quantification of PD-L1 expression in non-small cell lung cancer
    Verma, Vivek
    Chang, Joe Y.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S402 - S404